0.529
0.00 (-0.04%)
| Penutupan Terdahulu | 0.529 |
| Buka | 0.529 |
| Jumlah Dagangan | 455,804 |
| Purata Dagangan (3B) | 2,776,783 |
| Modal Pasaran | 51,869,092 |
| Harga / Jualan (P/S) | 247.76 |
| Harga / Buku (P/B) | 0.830 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| EPS Cair (TTM) | -0.800 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 17.35% |
| Nisbah Semasa (MRQ) | 7.80 |
| Aliran Tunai Operasi (OCF TTM) | -62.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -37.33 M |
| Pulangan Atas Aset (ROA TTM) | -39.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | aTyr Pharma, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.00 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.23% |
| % Dimiliki oleh Institusi | 69.63% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |